DDX41 and COVID-19: A booster dose increases the level of Abs with cross-reactivity against distinct SARS-CoV-2 variants of concern (VOCs).[32] These findings imply that maintaining a high level of SARS-CoV-2-specific Abs through repeated immunization is adequate to suppress COVID-19 caused by existing antigenic variations.